Analysts forecast that Viewray Inc (NASDAQ:VRAY) will post sales of $20.09 million for the current quarter, according to Zacks. Three analysts have issued estimates for Viewray’s earnings, with the lowest sales estimate coming in at $19.42 million and the highest estimate coming in at $20.44 million. Viewray posted sales of $16.13 million in the same quarter last year, which suggests a positive year-over-year growth rate of 24.6%. The company is scheduled to report its next quarterly earnings results on Thursday, March 15th.
On average, analysts expect that Viewray will report full-year sales of $20.09 million for the current year, with estimates ranging from $33.54 million to $34.56 million. For the next fiscal year, analysts expect that the business will post sales of $85.90 million per share, with estimates ranging from $74.22 million to $102.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Viewray.
VRAY has been the subject of several recent analyst reports. Mizuho reaffirmed a “buy” rating and set a $12.00 price objective on shares of Viewray in a research note on Wednesday, October 25th. Northland Securities reaffirmed a “buy” rating and set a $10.00 price objective on shares of Viewray in a research note on Friday, November 17th. ValuEngine cut shares of Viewray from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub cut shares of Viewray from a “buy” rating to a “hold” rating in a research note on Saturday, December 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Viewray in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $11.58.
Shares of Viewray (NASDAQ VRAY) traded up $0.03 during trading hours on Friday, reaching $8.41. 358,800 shares of the company traded hands, compared to its average volume of 714,658. The stock has a market capitalization of $568.04, a PE ratio of -7.44 and a beta of -0.06. Viewray has a 12 month low of $4.40 and a 12 month high of $10.64. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67.
TRADEMARK VIOLATION WARNING: “$20.09 Million in Sales Expected for Viewray Inc (VRAY) This Quarter” was published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://weekherald.com/2018/03/14/20-09-million-in-sales-expected-for-viewray-inc-vray-this-quarter.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.